Clinical meaning
Bacterial vaginosis (BV) represents a polymicrobial dysbiosis of the vaginal microbiome characterized by depletion of hydrogen peroxide-producing Lactobacillus species and overgrowth of anaerobic and facultative bacteria. The healthy vaginal microbiome is classified into Community State Types (CSTs): CST-I (L. crispatus dominant - most protective), CST-II (L. gasseri), CST-III (L. iners - transitional, less protective), CST-V (L. jensenii), and CST-IV (diverse anaerobes - BV-associated). Transition from Lactobacillus-dominant CSTs to CST-IV is the molecular hallmark of BV. Gardnerella vaginalis is the primary architect of BV pathogenesis through its unique biofilm-forming capacity. G. vaginalis produces sialidase, an enzyme that cleaves sialic acid residues from the protective mucin layer (MUC1, MUC4) coating vaginal epithelial cells, exposing adhesion receptors and facilitating bacterial attachment. The biofilm is a structured polymicrobial community embedded in an extracellular polysaccharide matrix that provides physical protection against antibiotics and host immune defenses. Within this biofilm, Atopobium vaginae acts synergistically with Gardnerella - A. vaginae has intrinsic metronidazole resistance (lacks nitroreductase enzymes required for prodrug activation) and perpetuates biofilm integrity after antibiotic treatment. The anaerobic shift in BV alters vaginal biochemistry. Prevotella...